Forma Medical Announces Strategic Focus on OptimalMTP™, Issuance of Key Methods Patent, and Appointment of Aaron Smith to Board of Directors

CAMP HILL, Pa.--(BUSINESS WIRE)--Forma Medical Inc. announced a sharpened strategic focus on OptimalMTP™, a procedural innovation enabling minimally invasive plating of first metatarsophalangeal (MTP) joint fusion, along with the issuance of a key methods patent and the appointment of Aaron Smith, former CEO of Artelon, to its Board of Directors.

The commercial growth of OptimalMTP™ has accelerated since its launch, with demonstrated clinical success in over 650 patients. Building on this clinical and commercial momentum, Forma Medical is prioritizing its resources to drive the continued growth of the OptimalMTP™ procedure. The company believes this focus will accelerate surgeon adoption, deepen clinical evidence, and establish OptimalMTP™ as the category-defining solution for MTP fusion.

Forma Medical also announced the issuance of U.S. Patent No. 12,521,157. The newly issued patent secures broad method claims covering minimally invasive joint fixation with a low-profile plating construct delivered through limited incisions, protecting critical procedural innovations. These methods enable surgeons to apply the gold-standard plate-and-screw construct using minimally invasive techniques, aligning trusted surgical biomechanics with modern patient expectations.

Building on this momentum, Forma has appointed Aaron Smith to its Board of Directors. Mr. Smith brings more than two decades of leadership experience in orthopedic medical devices. He most recently served as CEO of Artelon, which was acquired by Stryker, and has a proven track record of advancing patient care, driving commercial adoption, and navigating strategic transactions.

“This patent protects the technology that allows surgeons to achieve both minimally invasive procedures and decades of proven biomechanics: exactly what our mission is about,” said Andrew C. Davison, CEO of Forma Medical. “OptimalMTP™ brings these two critical goals together, and the strong clinical adoption shows how much this capability is needed. With a sharpened strategic focus and the addition of Aaron Smith to our Board, Forma is well positioned to lead the evolution in MTP fusion.”

Forma Medical will showcase its latest advancements at the upcoming American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference in Las Vegas from February 23–27, 2026.

About Forma Medical

Forma Medical Inc. is a privately held orthopedic device company focused on developing differentiated solutions that combine strong biomechanical principles with minimally invasive surgical techniques. The company’s flagship OptimalMTP™ system is designed to advance the standard of care in first MTP joint fusion by delivering stability, reproducibility, and efficiency through an MIS approach.